Haoqiang Ying

Correction to: Nature https://doi.org/10.1038/nature21064 Published online 8 February 2017 In the version of this article initially published, in Extended Data Fig. 10d, the image showing CC3 staining/EPI tumors treated with AUY922 (d10) was duplicated from the image showing CC3 staining/EPI tumors vehicle treated (d10). Due to the age of the article, the figure cannot be updated directly. We provide the corrected figure and the raw data as Supplementary Information accompanying this amendment.

Abstract Adenosine deaminase acting on RNA 1 (ADAR1) contributes to immunotherapy resistance by suppressing interferon signaling. Therapeutic targeting of ADAR1 has not been achieved to date in clinical settings. Here, we discover all-trans retinoic acid (ATRA) promotes ADAR1 protein degradation in cancer. In addition, ATRA induces PD-L1 and combination of ATRA and PD-1 blockade reprograms tumor microenvironments to unleash antitumor immunity, thereby impeding tumor growth.

Correction to: Nature https://doi.org/10.1038/nature13611 Published online 10 August 2014 Since the version of the article initially published, a sample mislabeling issue has been brought to the authors’ attention concerning the immunoblots shown in Figs. 4a and 2b. The samples in Fig. 4a should have been labeled as “No. 3” and “No. 4”, rather than “No. 1” and “No. 2” as originally indicated. An updated version of Fig. 4a with the corrected sample identifiers is shown below as Fig. 1.